Key considerations for cancer pharmacotherapy 2

Published on May 29, 2017   28 min
0:05
Now that we've introduced you to a variety of the different agents that we see in clinical practice, how does this actually translate into a treatment plan for a patient?
0:16
Let's take the example of breast cancer and look at the different modalities and sequencing of therapy that we can utilize. So we have traditional cytotoxic chemotherapy that is still a big part of the treatment of breast cancer. We commonly will use taxanes like paclitaxel and docetaxel, and anthracyclines like doxorubicin. We have a subset of breast cancers that are estrogen or progesterone receptor positive and so we didn't talk too much about hormonal therapy here but in breast cancer and prostate cancer and a few others, we do use hormonal therapy a lot. Tamoxifen is a selective estrogen receptor modulator and the aromatase inhibitors anastrozole, letrozole, exemestane, all inhibit estrogen in different ways. And then we also have our targeted therapy that I started to introduce. So again HER2 is expressed on about 20% to 30% of breast cancers, and we can target it with a monoclonal antibody trastuzumab. Pertuzumab is another monoclonal antibody that actually works to prevent the dimerization of HER2 with a family member that will cause an activating pathway. And then we also have lapatinib which is a tyrosine kinase inhibitor that binds on the inside of the cell directed towards HER2 as well.
Hide

Key considerations for cancer pharmacotherapy 2

Embed in course/own notes